CMPX Earnings & Financial Statements
Compass Therapeutics, Inc.
$0.88
+$0.02(+2.57%)
33
Overall
60
Value
18
Tech
21
Quality
Market Cap
$158.30M
Volume
4.97M
52W Range
$0.83 - $6.88
Target Price
$7.23
CMPX earnings and financial statements: Compass Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
CMPX Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | - | $850.0K | - | - | - |
| Operating income | -$72.84M | -$56.63M | -$50.36M | -$41.66M | -$81.88M |
| EBITDA | -$69.43M | -$47.62M | -$43.83M | -$39.75M | -$80.19M |
| Net income | -$66.49M | -$49.38M | -$42.49M | -$39.23M | -$82.18M |
| EPS (diluted) | $-0.42 | $-0.36 | $-0.33 | $-0.37 | $-1.31 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $219.59M | $140.40M | $156.88M | $199.65M | $153.76M |
| Total liabilities | $22.80M | $15.17M | $8.34M | $18.01M | $13.68M |
| Shareholders’ equity | $196.79M | $125.23M | $148.54M | $181.64M | $140.08M |
| Cash and equivalents | $30.64M | $43.48M | $24.23M | $34.95M | $144.51M |
| Long-term debt | $8.83M | $6.30M | $536.0K | $1.84M | $3.05M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$49.14M | -$44.85M | -$40.62M | -$34.13M | -$19.67M |
| Capital expenditure | -$25.0K | -$44.0K | -$30.0K | -$212.0K | -$1.57M |
| Free cash flow | -$49.17M | -$44.90M | -$40.65M | -$34.34M | -$21.23M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CMPX | $0.88 | +2.6% | 4.97M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Compass Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW